Stifel maintains Buy on Olema Pharmaceuticals, cuts target
Stifel maintained a Buy rating on Olema Pharmaceuticals and cut its price target to $30.00 from $48.00, per Benzinga.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.